Gundeep Dhillon

Dr. Gundeep Dhillon

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WTWen Tian
Wen Tian
SRStanley Glenn Rockson
Stanley Glenn Rockson
XJXinguo Jiang
Xinguo Jiang
JKJeanna Kim
Jeanna Kim
ABAdrian Begaye
Adrian Begaye
MNMark R Nicolls
Mark R Nicolls
Lymphedema is a common debilitating condition with very limited treatment options, and leukotriene B4may be a key pathogenic molecule and therapeutic target.

1 February 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
BMBryan G. Maxwell
Bryan G. Maxwell
JMJoshua J. Mooney
Joshua J. Mooney
PLPeter H. U. Lee
Peter H. U. Lee
JLJoseph E. Levitt
Joseph E. Levitt
LCLaveena Chhatwani
Laveena Chhatwani
GDGundeep Dhillon
Gundeep Dhillon
Rationale: In 2005, the lung allocation score (LAS) was implemented to prioritize organ allocation to minimize waiting-list mortality and maximize 1-year survival. It resulted in transplantation of older and sicker patients without changing 1-year survival. Its effect on resource use is unknown. Objectives: To determine changes in resource use over time in lung transplant admissions. Methods: Solid organ transplant recipients were identified within the Nationwide Inpatient Sample (NIS) data from 2000 to 2011. Joinpoint regression methodology was performed to identify a time point of change in mean total hospital charges among lung transplant and other solid-organ transplant recipients. Two temporal lung transplant recipient cohorts identified by joinpoint regression were compared for baseline characteristics and resource use, including total charges for index hospitalization, charges per day, length of stay, discharge disposition, tracheostomy, and need for extracorporeal membrane oxygenation. Measurements and Main Results: A significant point of increased total hospital charges occurred for lung transplant recipients in 2005, corresponding to LAS implementation, which was not seen in other solid-organ transplant recipients. Total transplant hospital charges increased by 40% in the post-LAS cohort ($569,942 [$53,229] vs. $407,489 [$28,360]) along with an increased median length of stay, daily charges, and discharge disposition other than to home. Post-LAS recipients also had higher post-transplant use of extracorporeal membrane oxygenation (odds ratio, 2.35; 95% confidence interval, 1.56–3.55) and higher incidence of tracheostomy (odds ratio, 1.52; 95% confidence interval, 1.22–1.89). Conclusions: LAS implementation is associated with a significant increase in resource use during index hospitalization for lung transplant.

10 September 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BMB. G. Maxwell
B. G. Maxwell
JLJ. E. Levitt
J. E. Levitt
BGB. A. Goldstein
B. A. Goldstein
JMJ. J. Mooney
J. J. Mooney
MNM. R. Nicolls
M. R. Nicolls
GDGundeep Dhillon
Gundeep Dhillon
Implementation of the lung allocation score (LAS) in 2005 led to transplantation of older and sicker patients without altering 1‐year survival. However, long‐term survival has not been assessed and emphasizing the 1‐year survival metric may actually sustain 1‐year survival while not reflecting worsening longer‐term survival. Therefore, we assessed overall and conditional 1‐year survival; and the effect of crossing the 1‐year threshold on hazard of death in three temporal cohorts: historical (1995–2000), pre‐LAS (2001–2005) and post‐LAS (2005–2010). One‐year survival post‐LAS remained similar to pre‐LAS (83.1% vs. 82.1%) and better than historical controls (75%). Overall survival in the pre‐ and post‐LAS cohorts was also similar. However, long‐term survival among patients surviving beyond 1 year was worse than pre‐LAS and similar to historical controls. Also, the hazard of death increased significantly in months 13 (1.44, 95% CI 1.10–1.87) and 14 (1.43, 95% CI 1.09–1.87) post‐LAS but not in the other cohorts. While implementation of the LAS has not reduced overall survival, decreased survival among patients surviving beyond 1 year in the post‐LAS cohort and the increased mortality occurring immediately after 1 year suggest a potential negative long‐term effect of the LAS and an unintended consequence of increased emphasis on the 1‐year survival metric.

25 January 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
CSCiara M. Shaver
Ciara M. Shaver
NWNancy Wickersham
Nancy Wickersham
JMJ. Brennan McNeil
J. Brennan McNeil
HNHiromasa Nagata
Hiromasa Nagata
AMAdam Miller
Adam Miller
LWLorraine B. Ware
Lorraine B. Ware
Primary graft dysfunction (PGD) is acute lung injury within 72 hours of lung transplantation. We hypothesized that cell-free hemoglobin (CFH) contributes to PGD by increasing lung microvascular permeability and tested this in patients, ex vivo human lungs, and cultured human lung microvascular endothelial cells. In a nested case control study of 40 patients with severe PGD at 72 hours and 80 matched controls without PGD, elevated preoperative CFH was independently associated with increased PGD risk (odds ratio [OR] 2.75, 95%CI, 1.23–6.16, P = 0.014). The effect of CFH on PGD was magnified by reperfusion fraction of inspired oxygen (FiO 2 ) ≥ 0.40 (OR 3.41, P = 0.031). Isolated perfused human lungs exposed to intravascular CFH (100 mg/dl) developed increased vascular permeability as measured by lung weight (CFH 14.4% vs. control 0.65%, P = 0.047) and extravasation of Evans blue–labeled albumin dye (EBD) into the airspace ( P = 0.027). CFH (1 mg/dl) also increased paracellular permeability of human pulmonary microvascular endothelial cell monolayers (hPMVECs). Hyperoxia (FiO 2 = 0.95) increased human lung and hPMVEC permeability compared with normoxia (FiO 2 = 0.21). Treatment with acetaminophen (15 μg/ml), a specific hemoprotein reductant, prevented CFH-dependent permeability in human lungs ( P = 0.046) and hPMVECs ( P = 0.037). In summary, CFH may mediate PGD through oxidative effects on microvascular permeability, which are augmented by hyperoxia and abrogated by acetaminophen.

11 September 2015 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
CHCharles Hill
Charles Hill
BMBryan Maxwell
Bryan Maxwell
DBDavid Boulate
David Boulate
FHFrancois Haddad
Francois Haddad
RHRichard Ha
Richard Ha
GDGundeep Dhillon
Gundeep Dhillon

27 September 2009 in Transplantation
Verified
Journal Article
Closed access
GDGundeep Dhillon
Gundeep Dhillon
JLJoseph Levitt
Joseph Levitt
HMHari Mallidi
Hari Mallidi
VVVincent G. Valentine
Vincent G. Valentine
MGMeera R. Gupta
Meera R. Gupta
DWDavid Weill
David Weill
Background. The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients. Methods. Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs. Results. We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1- and 5-year survival. However, donor HBcAb status did not impact 1- or 5-year survival posttransplant. Conclusions. Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.